Report overview
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF levels remain steady. However, in a patient with rheumatoid arthritis, the level of TNF is increasing which leads to more inflammation. TNF inhibitor drugs act as blockers for TNF substances. TNF alpha blockers are highly effective in the treatment of patients with active rheumatoid arthritis. These drugs are used in patients as a conventional second-line treatments.
This report aims to provide a comprehensive presentation of the global market for TNF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding TNF Inhibitors. This report contains market size and forecasts of TNF Inhibitors in global, including the following market information:
Global TNF Inhibitors Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global TNF Inhibitors market was valued at US$ 43420 million in 2022 and is projected to reach US$ 46850 million by 2029, at a CAGR of 1.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The adalimumab segment is likely to expand at a significant pace during the forecast period. The drug is effectively used in a broad range of pain management therapies and is widely available over the counter. Based on distribution channel, the TNF inhibitors market can be segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment is likely to expand at a significant pace between 2017 and 2025, this is because patients with rheumatoid arthritis, arthritis give more preference to the hospitals for treatment. Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are some of the factors that drive the TNF inhibitors market. According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Center for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. Owing to this, the consumption of TNF inhibitor dugs is likely to increase rapidly in the near future. However, side-effects associated with the use of TNF inhibitor drugs such as skin irritation, flushing, headache, and abdominal pain are estimated to hinder the market in the next few years.
We surveyed the TNF Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global TNF Inhibitors Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global TNF Inhibitors Market Segment Percentages, by Type, 2022 (%)
Monotherapy
Combination Therapy
Global TNF Inhibitors Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global TNF Inhibitors Market Segment Percentages, by Application, 2022 (%)
Skin Disease
Ankylosing Spondylitis
Gastrointestinal Disease
Rheumatoid Arthritis
Others
Global TNF Inhibitors Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global TNF Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies TNF Inhibitors revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies TNF Inhibitors revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Boehringer Ingelheim
Amgen
BioPharma
Mochida Pharmaceutical
Hanall
Outline of Major Chapters:
Chapter 1: Introduces the definition of TNF Inhibitors, market overview.
Chapter 2: Global TNF Inhibitors market size in revenue.
Chapter 3: Detailed analysis of TNF Inhibitors company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of TNF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
